Idexx Laboratories price target raised to $700 from $550 at BofA

BofA raised the firm’s price target on Idexx Laboratories (IDXX) to $700 from $550 and keeps a Neutral rating on the shares. The company posted a strong Q2 print, spurring a major move higher as the quarter “checked all the boxes,” the analyst tells investors in a research note. The firm added that it is encouraged by the Q2 results and acknowledges the very strong performance year-to-date, but sees less and less room for further upside at these levels.